Pith. sign in

Reference change · event page

Reference changes · DOI

Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types

Published notice on a work cited in the Pith corpus. Exact quotes below. No model judges whether any citation was load-bearing.

This page records that a citing paper's bibliography includes a work with a published notice. It is not a judgment on the citing paper.

Correction Crossref 1 open · 1 total · 0 disputed
DOI
10.1136/jitc-2024-010311
Notice DOI
10.1136/jitc-2024-010311corr1
Event date
2025-03-03
Machine twin
JSON

01One-hop citing occurrences

Correction Open
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

ref [4] · 2509.04939 · notice #8477 · dispute

Raw extraction · citation context

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol . 2017;18(3):e143 -e152. doi:10.1016/S1470-2045(17)30074-8 4. Gandara DR, Agarwal N, Gupta S, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025;13(2):e010311. doi:10.1136/jitc-2024-010311 5. Ngo P, Cooper WA, Wade S, et al. Why PD -L1 expression varies between studies of lung cancer: results from a Bayesian meta -analysis. Sci Rep . 2025;15(1):4166. doi:10.1038/s41598-024-80301-9 6. Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal -Anal Task Forces whitepaper.

Parser render (TeX stripped for reading; raw above is the evidence)

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol . 2017;18(3):e143 -e152. doi:10.1016/S1470-2045(17)30074-8 4. Gandara DR, Agarwal N, Gupta S, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025;13(2):e010311. doi:10.1136/jitc-2024-010311 5. Ngo P, Cooper WA, Wade S, et al. Why PD -L1 expression varies between studies of lung cancer: results from a Bayesian meta -analysis. Sci Rep . 2025;15(1):4166. doi:10.1038/s41598-024-80301-9 6. Dasari A, Morris VK, Allegra CJ, et al. ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal -Anal Task Forces whitepaper

Status lifecycle on notices: open → disputed → (response attached on the notice page). Repaired counts matter as much as open counts. There is no “safe,” “invalid,” or “resolved” badge.